Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States
- PMID: 28052152
- PMCID: PMC5538773
- DOI: 10.1001/jamacardio.2016.5139
Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States
Erratum in
-
Incorrectly Spelled Author Name.JAMA Cardiol. 2017 Mar 1;2(3):346. doi: 10.1001/jamacardio.2017.0154. JAMA Cardiol. 2017. PMID: 28297017 No abstract available.
Abstract
Importance: The Second Universal Definition of Myocardial Infarction (MI) divides MIs into different types. Type 1 MIs result spontaneously from instability of atherosclerotic plaque, whereas type 2 MIs occur in the setting of a mismatch between oxygen demand and supply, as with severe hypotension. Type 2 MIs are uncommon in the general population, but their frequency in human immunodeficiency virus (HIV)-infected individuals is unknown.
Objectives: To characterize MIs, including type; identify causes of type 2 MIs; and compare demographic and clinical characteristics among HIV-infected individuals with type 1 vs type 2 MIs.
Design, setting, and participants: This longitudinal study identified potential MIs among patients with HIV receiving clinical care at 6 US sites from January 1, 1996, to March 1, 2014, using diagnoses and cardiac biomarkers recorded in the centralized data repository. Sites assembled deidentified packets, including physician notes and electrocardiograms, procedures, and clinical laboratory tests. Two physician experts adjudicated each event, categorizing each definite or probable MI as type 1 or type 2 and identifying the causes of type 2 MI.
Main outcomes and measures: The number and proportion of type 1 vs type 2 MIs, demographic and clinical characteristics among those with type 1 vs type 2 MIs, and the causes of type 2 MIs.
Results: Among 571 patients (median age, 49 years [interquartile range, 43-55 years]; 430 men and 141 women) with definite or probable MIs, 288 MIs (50.4%) were type 2 and 283 (49.6%) were type 1. In analyses of type 1 MIs, 79 patients who underwent cardiac interventions, such as coronary artery bypass graft surgery, were also included, totaling 362 patients. Sepsis or bacteremia (100 [34.7%]) and recent use of cocaine or other illicit drugs (39 [13.5%]) were the most common causes of type 2 MIs. A higher proportion of patients with type 2 MIs were younger than 40 years (47 of 288 [16.3%] vs 32 of 362 [8.8%]) and had lower current CD4 cell counts (median, 230 vs 383 cells/µL), lipid levels (mean [SD] total cholesterol level, 167 [63] vs 190 [54] mg/dL, and mean (SD) Framingham risk scores (8% [7%] vs 10% [8%]) than those with type 1 MIs or who underwent cardiac interventions.
Conclusions and relevance: Approximately half of all MIs among HIV-infected individuals were type 2 MIs caused by heterogeneous clinical conditions, including sepsis or bacteremia and recent use of cocaine or other illicit drugs. Demographic characteristics and cardiovascular risk factors among those with type 1 and type 2 MIs differed, suggesting the need to specifically consider type among HIV-infected individuals to further understand MI outcomes and to guide prevention and treatment.
Conflict of interest statement
The following have no conflicts of interest to report: H Crane, P Crane, Kitahata, Rodriguez, Drozd, Mathews, Napravnik, Moore, Nance, Peter, Crothers, Feinstein, Delaney, McReynolds, Heckbert, Peter, Paramsothy, Geng, Barnes, Grunfeld, and Lober. The following have received grant support or served as consultants: Dr Hunt with Merck and Gilead, Dr. Greer with DefiniCare, Dr. Willig with DefiniCare, BMS, Gilead, Pfizer, and Tibotect, Dr. Saag with BMS, BI, Abbvie, Gilead, Merck, and ViiV, Dr. Mugavero with BMS, Gilead, Merck, Pizer, DefiniCare, Dr. Eron with Merck, Glaxo Smith Kline, ViiV, BMS, Abbvie, Gilead, Tibotec/Janssen, Dr. Hsue with Gilead and Pfizer, and Dr. Budoff has consulted for General Electric.
References
-
- Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec’s public health insurance database. J Acquir Immune Defic Syndr. 57(3):245–253. - PubMed
-
- Mondy K, Tebas P. Cardiovascular risks of antiretroviral therapy. Annu Rev Med. 2007;58:141–155. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials